Takeda

July 18, 2018

Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial

News

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase ... Read more

July 9, 2018July 9, 2018

Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows

News

Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to ... Read more

February 9, 2018February 9, 2018

Multiple Myeloma Patients in UK Gain Access to Ninlaro through Cancer Drugs Fund

News

Multiple myeloma patients in the United Kingdom can now potentially benefit from a new oral pill sold as Ninlaro (ixazomib) after Takeda, the maker of the medicine, struck a ... Read more

June 28, 2017June 28, 2017

Potential Use of Ninlaro as Maintenance Therapy in Multiple Myeloma Shown in Phase 1/2 Trials

News

Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according to long-term follow-up data ... Read more

April 14, 2016

Documentary on Myeloma Supporters Who Climbed Kilimanjaro Premiered in Miami

News

Advocates working to raise awareness and funds for multiple myeloma successfully climbed Mount Kilimanjaro, and a documentary about the climb premiered last month at the Eden Roc Miami. The group ... Read more